Search clinical trials for: Peginterferon alfa

Total 3151 results

Baptist Health South Florida
Regeneron Pharmaceuticals

Withdrawn

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Advanced Squamous Cell Carcinoma

United States
José Antonio Carrion
Instituto de Salud Carlos III

Completed

HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients

Chronic Hepatitis B (HBeAg-negative)
University of Pittsburgh
Schering-Plough

Terminated

Pilot Study of IFN α2b for Melanoma Patients

Melanoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

United States
Beijing 302 Hospital

Recruiting

Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

Chronic Hepatitis B

China
Beijing 302 Hospital

Recruiting

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

Chronic Hepatitis B

China
Seoul National University Hospital

Completed

Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection (E+VIP)

Hepatitis B, Chronic

Korea, Republic of
The Wistar Institute
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Unknown

Reducing Proviral HIV DNA With Interferon-a (BEAT-HIV)

HIV/AIDS | HIV

United States
Beijing Kawin Technology Share-Holding Co., Ltd.

Completed

Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C

Chronic Hepatitis c

China
National Taiwan University Hospital

Completed

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.

COVID-19

Taiwan
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

New Zealand, Poland, France
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Hepatitis C, Chronic

United States, Canada, Slovakia, Poland, New Zealand, France, Australia
Aiwu Ruth He, MD
Merck Sharp & Dohme LLC; Georgetown University; The Cleveland Clinic; Hoosier Cancer... and other collaborators

Terminated

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

Advanced Cholangiocarcinoma

United States
Weill Medical College of Cornell University
Vertex Pharmaceuticals Incorporated

Completed

Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)

Hepatitis C
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

Melanoma
PV-Nord

Completed

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

Polycythemia Vera

France
Chinese University of Hong Kong
Hoffmann-La Roche

Completed

Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment

Chronic Hepatitis B

China
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)

Hepatitis C, Chronic

Russian Federation, Korea, Republic of
University of Chicago

Terminated

Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients

Hepatitis C

United States
Kirby Institute

Completed

Treatment of Recently Acquired Hepatitis C Virus Infection (ATAHC-II)

Acute Hepatitis C

Australia
Chugai Pharmaceutical

Completed

Trial of Pegasys® in Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
National Taiwan University Hospital

Not yet recruiting

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities

COVID-19

Taiwan
PharmaEssentia Japan K.K.

Recruiting

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Polycythemia Vera (PV)

Japan
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) (NEXT-1)

Hepatitis C, Chronic
Eiger BioPharmaceuticals

Completed

Lonafarnib With and Without Ritonavir in HDV (LOWR-1) (LOWR-1)

Chronic Hepatitis D Infection

Turkey
Emory University
CURE Childhood Cancer, Inc.

Completed

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Juvenile Pilocytic Astrocytomas | Optic Pathway Gliomas

United States
University of Nebraska

Terminated

Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers

Chronic Hepatitis C | Relapse | Genotype 1

United States
Hoffmann-La Roche

Completed

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Renal Cell Carcinoma | Chronic Myelogenous Leukemia | Malignant Melanoma

Canada, India, Bulgaria, Russian Federation, Spain, South Africa, Slovakia
Huashan Hospital

Unknown

Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy

Chronic Hepatitis B

China
National Institute of Allergy and Infectious Diseases...

Completed

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

HIV Infections | Hepatitis C | Liver Disease

United States, Puerto Rico
Hospital Carlos III, Madrid

Unknown

Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients (PERICO)

Chronic Hepatitis C

Spain
Hoffmann-La Roche

Completed

An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

Hepatitis C, Chronic

Hungary
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Rennes University Hospital

Completed

Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.

Hepatitis C, Chronic | Liver Fibrosis

France, Belgium
sigma-tau i.f.r. S.p.A.
SciClone Pharmaceuticals

Completed

Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

Chronic Hepatitis C

Spain, Italy, France, Germany, Greece
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Breast Cancer | Metastatic Cancer

United States
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

Essential Thrombocytopenia

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Hepatitis C, Chronic

Australia, United States, Italy, France, Puerto Rico, Taiwan, United Kingdom, Greece, Poland, Brazil, Spain
Weill Medical College of Cornell University
Schering-Plough

Completed

Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects

Chronic Hepatitis C
Hepatitis Resource Network
Hoffmann-La Roche

Completed

PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy

Chronic Hepatitis C Virus Infection

United States
University of Utah
Schering-Plough

Terminated

Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

Gastrointestinal Stromal Tumors | Solid Tumors | Cancer Brain

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Completed

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Recurrence | Hematological Neoplasms

China
University of Nebraska

Withdrawn

Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients

Chronic Hepatitis C

United States
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

Hepatitis C, Chronic

Australia, France, Italy, Spain, Germany, United States, Canada, Austria, Puerto Rico
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
Merck Sharp & Dohme LLC

Completed

5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)

Hepatitis C, Chronic
Gilead Sciences

Completed

Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

Germany, Belgium, United Kingdom, France

3

Subscribe